Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUWOLFIA SERPENTINA vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Hypertension,Management of agitated psychotic states (historical use)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Hepatic metabolism via CYP450 enzymes, with active metabolites (e.g., reserpine is metabolized by hydrolysis and conjugation); significant first-pass effect.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Plasma protein binding: approximately 80-90%, primarily to alpha1-acid glycoprotein and albumin.
~10-20% bound to plasma proteins (primarily albumin).
Vd: 0.5-1.0 L/kg. High tissue distribution, especially to adipose tissue and brain, correlating with extensive accumulation.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral bioavailability: approximately 50% (range 30-60%) due to first-pass metabolism. Not administered parenterally in clinical practice.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
Not studied; avoid use in severe renal impairment (GFR <30 m L/min) due to risk of accumulation and CNS effects.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in Child-Pugh A/B; consider 50% dose reduction.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not recommended in children <12 years. For ages ≥12: 100 µg/kg twice daily, max 50 mg/dose.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Start at lowest dose (50 mg once daily) and titrate slowly; monitor for CNS depression, orthostatic hypotension, and depression.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
None
None
Risk of severe depression and suicide; use with caution in patients with history of depression. May cause bradycardia, electrolyte disturbances, and gastrointestinal bleeding. Avoid abrupt discontinuation to prevent withdrawal symptoms. Possible extrapyramidal symptoms and parkinsonism.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Active peptic ulcer, ulcerative colitis, history of depression (especially with suicidal tendencies), electroconvulsive therapy, pheochromocytoma, and concomitant MAO inhibitors.
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as Rauwolfia may potentiate pressor effects. Limit alcohol intake. No specific food restrictions otherwise; but taking with food may reduce gastrointestinal upset.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Rauwolfia serpentina (reserpine) is Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimesters: May cause neonatal bradycardia, hypotonia, and nasal congestion due to placental transfer. Use only if benefit outweighs risk.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Rauwolfia alkaloids (reserpine) are excreted into breast milk. M/P ratio is not established. Avoid breastfeeding due to potential for infant hypotension, bradycardia, and extrapyramidal effects. Alternative therapy recommended.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No specific dose adjustments are established; however, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use lowest effective dose and monitor maternal response closely.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
1. Rauwolfia serpentina (reserpine) depletes catecholamines and serotonin from central and peripheral nerve endings; onset of action is slow (weeks) and offset prolonged. 2. Use cautiously in patients with history of peptic ulcer disease due to increased gastric acid secretion. 3. May cause significant bradycardia and orthostatic hypotension; monitor blood pressure and heart rate regularly. 4. Avoid concomitant use with MAOIs, tricyclic antidepressants, or sympathomimetics due to risk of hypertensive crisis. 5. Documented nasal congestion and sedation are common; consider alternative antihypertensives if tolerated poorly.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed; do not stop suddenly as this may cause rapid rise in blood pressure.,Rise slowly from sitting or lying down to minimize dizziness from low blood pressure.,Avoid alcohol, which can worsen dizziness and drowsiness.,Report persistent nasal congestion, stomach pain, or unusual tiredness to your doctor.,Use caution when driving or operating machinery until you know how this medication affects you.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUWOLFIA SERPENTINA vs ALDOMET, answered by our medical review team.
RAUWOLFIA SERPENTINA is a Antihypertensive that works by Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUWOLFIA SERPENTINA and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUWOLFIA SERPENTINA is: Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUWOLFIA SERPENTINA and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUWOLFIA SERPENTINA is classified as Category C. Rauwolfia serpentina (reserpine) is Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third . ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.